Ionis Pharmaceuticals Stock Beneish M Score

IONS Stock  USD 35.90  0.53  1.50%   
This module uses fundamental data of Ionis Pharmaceuticals to approximate the value of its Beneish M Score. Ionis Pharmaceuticals M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Ionis Pharmaceuticals Piotroski F Score and Ionis Pharmaceuticals Altman Z Score analysis.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.
  
At this time, Ionis Pharmaceuticals' Short and Long Term Debt Total is comparatively stable compared to the past year. Net Debt is likely to gain to about 1.1 B in 2024, despite the fact that Net Debt To EBITDA is likely to grow to (4.35). At this time, Ionis Pharmaceuticals' Debt To Equity is comparatively stable compared to the past year.
At this time, Ionis Pharmaceuticals' M Score is unavailable. The earnings manipulation may begin if Ionis Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Ionis Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Ionis Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.47
Beneish M Score - Unavailable
Elasticity of Receivables

1.0

Focus
Asset Quality

1.04

Focus
Expense Coverage

1.0

Focus
Gross Margin Strengs

1.05

Focus
Accruals Factor

1.0

Focus
Depreciation Resistance

0.91

Focus
Net Sales Growth

1.05

Focus
Financial Leverage Condition

1.0

Focus

Ionis Pharmaceuticals Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Ionis Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables102.7 M97.8 M
Sufficiently Up
Slightly volatile
Total Revenue827 M787.6 M
Sufficiently Up
Slightly volatile
Total Assets3.1 BB
Sufficiently Up
Slightly volatile
Total Current Assets2.8 B2.6 B
Sufficiently Up
Slightly volatile
Non Current Assets Total365.6 M348.2 M
Sufficiently Up
Slightly volatile
Property Plant Equipment79.6 M85.4 M
Significantly Down
Slightly volatile
Depreciation And Amortization23.6 M22.5 M
Sufficiently Up
Slightly volatile
Selling General Administrative244.2 M232.6 M
Sufficiently Up
Slightly volatile
Total Current Liabilities470.5 M448.1 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total2.3 B2.2 B
Sufficiently Up
Slightly volatile
Short Term Debt55.8 M53.2 M
Sufficiently Up
Slightly volatile
Long Term Debt1.3 B1.2 B
Sufficiently Up
Slightly volatile
Short Term InvestmentsB1.9 B
Sufficiently Up
Slightly volatile
Long Term InvestmentsMM
Fairly Down
Slightly volatile

Ionis Pharmaceuticals Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Ionis Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Ionis Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Ionis Pharmaceuticals' degree of accounting gimmicks and manipulations.

About Ionis Pharmaceuticals Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

23.62 Million

At this time, Ionis Pharmaceuticals' Depreciation And Amortization is comparatively stable compared to the past year.

Ionis Pharmaceuticals Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Ionis Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables63M76M62M25.5M97.8M102.7M
Total Revenue1.1B729M810M587M787.6M827.0M
Total Assets3.2B2.4B2.6B2.5B3.0B3.1B
Total Current Assets2.7B2.1B2.3B2.2B2.6B2.8B
Net Debt(1.8B)(1.1B)(954M)(642M)1.1B1.1B
Short Term Debt2.0M293.2M3.5M7.5M53.2M55.8M
Long Term Debt770.0M515.7M1.2B1.2B1.2B1.3B
Operating Income366M(172M)(30M)(411M)(353.7M)(336.0M)
Investments(5.0M)315.5M212.8M(262.6M)24.7M26.0M

Ionis Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ionis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ionis Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

About Ionis Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ionis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ionis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ionis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.